Advertisement
Screener

Lantheus Holdings, Inc. (LNTH) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases

2.8 / 5 stars · 68/120 Roast Me

Lantheus Holdings, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases

Lantheus Holdings, Inc. (LNTH) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.

Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases · last filed 2022-02-24

  • Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2021-12-31 was $0.00.
  • Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2021-09-30 was $0.00.
  • Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2020-12-31 was $0.00.
  • Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for the quarter ending 2020-09-30 was $0.00.
  • Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
  • Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases for fiscal 2020 was $10.10M.
Period endFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 3 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 6 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 9 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 12 month
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$0.00
derived: sum of 2 quarters · filed 2022-02-24
$0.00
10-K · filed 2022-02-24
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$0.00
10-Q · filed 2021-11-04
2021-06-30$0.00
10-Q · filed 2021-07-28
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$0.00
derived: sum of 2 quarters · filed 2022-02-24
$10.10M
derived: sum of 3 quarters · filed 2022-02-24
$10.10M
10-K · filed 2022-02-24
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$10.10M
derived: sum of 2 quarters · filed 2021-11-04
$10.10M
10-Q · filed 2021-11-04
2020-06-30$10.10M
10-Q · filed 2020-07-31
$10.10M
10-Q · filed 2021-07-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Celldex Therapeutics, Inc. (CLDX)United States$2.471B-9.72
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B